Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | PDXK | O00764 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902480 | 1.00 | KDR (0.56) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL4556432 | 0.95 | KDR (0.64) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL29902462 | 0.88 | KDR (0.71) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL2062492 | 0.88 | KDR (0.71) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| Hydrochloric Acid SCHEMBL28914336 | 0.88 | KDR (0.70) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL2063302 | 0.86 | PDGFRB (0.50) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL29902482 | 0.86 | PDGFRB (0.50) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL19056203 | 0.86 | MET (0.49) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL2063822 | 0.85 | KDR (0.53) | KDRPDGFRBPDGFRAFGFR2AURKB | |
| SCHEMBL21884829 | 0.85 | PDGFRB (0.57) | KDRPDGFRBPDGFRAFGFR2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125776-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2017-07-05 | — | — | EP | claimed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | claimed |
| EP-2125776-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2125776-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES LLC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148532-B2 | Benzyl 1-((4-(1H-indol-5-ylamino)-6-methoxyquinolin-7-yloxy)methyl)cyclopropylcarbamate; cancers associated with protein tyrosine kinases | CHEN GUOQING PAUL (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2008112407-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227811-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | KDR 2/4885PDGFRB 6/4885PDGFRA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.